Premium
A single‐tube flow cytometric procedure for enhancing the diagnosis and prognostic classification of patients with myelodysplastic syndromes
Author(s) -
Kárai B.,
Bedekovics J.,
Miltényi Zs.,
Gergely L.,
Szerafin L.,
Ujfalusi A.,
Kappelmayer J.,
Hevessy Zs.
Publication year - 2017
Publication title -
international journal of laboratory hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.705
H-Index - 55
eISSN - 1751-553X
pISSN - 1751-5521
DOI - 10.1111/ijlh.12700
Subject(s) - myelodysplastic syndromes , medicine , cohort , gastroenterology , flow cytometry , pathology , immunology , bone marrow
We created a simple and effective flow cytometry scoring system ( FCSS ) for suspected Myelodysplastic syndromes ( MDS ) samples and evaluated its diagnostic and prognostic potential. Methods Besides evaluating the four parameters suggested by Ogata, we investigated erythroid precursors and mast cells. We evaluated the six‐parameter FCSS in a four‐color setting (test cohort: 51 patients; 25 controls), then we implemented it into an eight‐color setting and tested it on a validation cohort of patients with MDS (n=31). Results When we compared MDS cases to non‐ MDS samples in the test cohort, we detected significant differences regarding not only the four major parameters but also two additional ones, namely CD 71 rCV % of erythroid precursors ( P =.004) and mast cell percentage ( MC %) ( P =.001). The utilization of the modified six‐parameter FCSS provided high sensitivity and specificity both in the four color (84% and 80%, respectively) and in the eight color (81% and 100%, respectively) setting, with an excellent discriminative power between MDS and non‐ MDS samples. Furthermore, we found significant difference in event‐free survival between the risk groups based on the modified six‐parameter FCSS ( P =.001). Conclusion We evaluated and validated a single‐tube flow cytometric procedure for a simple six‐parameter FCSS which has not only high diagnostic but also prognostic power.